Johnes Disease Diagnostics Market: Market Size & Forecast 2026

Johne's disease, also known as paratuberculosis, is a contagious, chronic, and usually fatal bacterial infection discovered in 1905 by German bacteriologist Heinrich Johne. It primarily targets the small intestine of ruminants, notably cattle, causing progressive intestinal thickening that impairs nutrient absorption, leading to weight loss, reduced milk production, and eventual death, all while the animal retains a healthy appetite. The global diagnostics market, valued at approximately $0.74 billion in 2025, encompasses diagnostic tests such as ELISA antibody assays, PCR-based molecular tests, and culture-based methods used by veterinarians, livestock producers, and government agencies to detect, monitor, and control the disease.

• •Johne's disease is endemic worldwide, including in the United States, and affects primarily cattle but also other ruminant species
• •Diagnostics include ELISA antibody tests, PCR, and bacterial culture methods targeting Mycobacterium avium subspecies paratuberculosis (MAP)
• •The disease is incurable and progressive, making early detection through diagnostics critical for herd management

A primary driver is the substantial economic burden imposed by Johne's disease, with dairy and beef producers facing losses from reduced milk yields, premature culling, and trade restrictions. Governments in North America and Europe have implemented national control and eradication programs, such as the USDA's Voluntary Johne's Disease Herd Certification Program, which mandate or strongly encourage regular herd testing. Rising global demand for safe animal protein, increasing livestock production in emerging markets, and heightened biosecurity awareness following animal disease outbreaks all contribute to sustained demand for reliable diagnostics.

• •Losses from reduced milk production, premature culling, and trade barriers incentivize livestock producers to test regularly
• •Government-led eradication and certification programs in the US, Canada, EU, and Australia create structured, recurring demand for diagnostic tests
• •Growing global meat and dairy consumption drives demand for herd health management tools including Johne's disease testing

The market is typically segmented by product type, ELISA kits, PCR diagnostics, immunofluorescence assays, and culture-based tests, with ELISA remaining the most widely used method due to its cost-effectiveness for large-scale herd screening. By animal type, cattle dominate the market given the disease's significant economic impact on dairy herds. North America and Europe hold the largest market shares, supported by mature veterinary infrastructure, strict regulatory frameworks, and well-established eradication programs. The Asia-Pacific and Latin American regions are expected to see relatively faster growth as commercial livestock farming expands and disease surveillance capacity improves.

• •ELISA-based antibody testing holds the largest share, with PCR-based molecular diagnostics growing fastest due to improved sensitivity and speed
• •Cattle (especially dairy) represent the dominant animal segment, with small ruminants representing a smaller but growing market
• •North America leads in market share, while Asia-Pacific and Latin America are emerging as faster-growing regions

What are the recent trends and outlook?

The market is moving toward more sensitive, rapid, and multiplex diagnostic platforms that can simultaneously test for Johne's disease and other livestock pathogens. Integration of diagnostic results into digital herd-management software is an emerging trend, enabling producers to make data-driven culling and management decisions. There is also growing research interest in the potential zoonotic link between MAP and Crohn's disease in humans, which may spur additional regulatory and consumer-driven demand for testing. Over the forecast horizon, the market's compound annual growth rate of 6.21% is expected to remain steady, supported by ongoing intensification of global livestock farming and continued expansion of government-mandated disease surveillance programs.

• •Molecular and point-of-care diagnostic technologies are gaining share, offering faster results and improved on-farm usability
• •Integration of Johne's testing data into herd-management software platforms is enabling proactive, data-driven disease control strategies
• •Research into potential links between MAP and human Crohn's disease could influence future regulatory requirements and testing demand